(NASDAQ: SVRA) Savara's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Savara's earnings in 2025 is -$115,645,000.On average, 10 Wall Street analysts forecast SVRA's earnings for 2025 to be -$107,247,901, with the lowest SVRA earnings forecast at -$105,681,199, and the highest SVRA earnings forecast at -$106,820,619. On average, 9 Wall Street analysts forecast SVRA's earnings for 2026 to be -$87,755,682, with the lowest SVRA earnings forecast at -$111,663,153, and the highest SVRA earnings forecast at -$34,182,598.
In 2027, SVRA is forecast to generate -$61,630,410 in earnings, with the lowest earnings forecast at -$120,636,085 and the highest earnings forecast at -$38,455,423.